Results 101 to 110 of about 2,175,372 (155)

Tumor-derived annexin A1 drives lenvatinib resistance by regulating SOX2/STAT3/S100A6 feedback loop and M2 macrophage polarization in hepatocellular carcinoma

Lenvatinib has been approved by the FDA as a front-line treatment for advanced hepatocellular carcinoma (HCC), but its survival benefits are limited by acquired drug resistance.
Martina Mang Leng Lei, Carmen Oi Ning Leung, Gregory Kenneth Muliawan, Rainbow Wing Hei Leung, Wing Ki Chau, Stephanie Ma, Catherine Yu Jia Gu, Qian Qian Yu, Xin Wang, Jin Ding, Xiao Qi Wu, Terence Kin Wah Lee, Ming Liu, Sze Man Chan, Yuan Gao, Yi Tian Chen   +15 more
core   +1 more source

Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular CarcinomaSummary

Cellular and Molecular Gastroenterology and Hepatology
Background & Aims: Hepatocellular carcinoma (HCC), the dominant form of liver cancer, is a leading cause of cancer death worldwide. Sorafenib and lenvatinib have long been the 2 limited options of first-line treatments for patients with unresectable ...
Ting-Chi Rebecca Wan, Lai Wei, Lai-Hung Cheng, Wai-Ching Chin, Jialing Shen, For-Fan Chan, Zhijian Kuang, Cun Wang, Carmen Chak-Lui Wong, Chun-Ming Wong   +9 more
doaj   +1 more source

Activation of Nerve Growth Factor signaling limits the response to lenvatinib in hepatocellular carcinoma

Signal Transduction and Targeted Therapy
Resistance to lenvatinib remains a major barrier in the treatment of advanced hepatocellular carcinoma (HCC), underscoring the urgent need to elucidate the underlying mechanisms and identify actionable therapeutic targets.
Minghao Xu, Yimin Zheng, Longtao Zhao, Siwei Wang, Junbo Chen, Zhongchi Fu, Aying Ma, Bugang Liang, Yilan Huang, Haihan Xu, Yue Wang, Yingjie Ai, Haiying Zeng, Chao Gao, Jiabin Cai, Aiwu Ke, Jia Fan   +16 more
doaj   +1 more source

Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion

Frontiers in Oncology
FGFR2 fusions occur in up to 14% of patients with intrahepatic cholangiocarcinoma (iCCA) and have been considered as therapeutic target for FGFR inhibitors (FGFRi).
Nadja Ballin, Alexander Ott, Olga Seibel-Kelemen, Irina Bonzheim, Dominik Nann, Janina Beha, Stephan Spahn, Stephan Singer, Stephan Ossowski, Cristiana Roggia, Christopher Schroeder, Michael Bitzer, Michael Bitzer, Sorin Armeanu-Ebinger   +13 more
doaj   +1 more source

Hepatitis B Virus-Induced Resistance to Sorafenib and Lenvatinib in Hepatocellular Carcinoma Cells: Implications for Cell Viability and Signaling Pathways

Background/Objectives: Sorafenib and lenvatinib are tyrosine kinase inhibitors used in hepatocellular carcinoma (HCC) treatment. This study investigates how hepatitis B virus (HBV) infection affects their efficacy in HepG2 hepatoma cells.
Romy Zemel, Narmen Esmael, Ran Tur-Kaspa, Ido Lubin   +3 more
core   +1 more source

Targeting immunosuppressive macrophages by CSRP2-regulated CCL28 signaling sensitizes hepatocellular carcinoma to lenvatinib

Journal for ImmunoTherapy of Cancer
Background Despite comparable survival benefit has been obtained, the drug resistance remarkably reduced lenvatinib clinical efficacy. Here, we aimed to identify the potential mechanism by which cysteine and glycine-rich protein 2 (CSRP2) regulates the ...
Xiaowu Huang, Zhiqiang Hu, Yu Gong, Jia Li, Pengcheng Wang, Changzhou Chen, Sheng Su, Xinming Ye, Songyang Yu, Zehuan Li   +9 more
doaj   +1 more source

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment

Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treatment
Stephen L. Chan, Landon L. Chan
core   +1 more source

AFP confers the resistance of lenvatinib in hepatocellular carcinoma by activating PI3K/AKT/LDHA signaling axis

Discover Oncology
This study aimed to explore whether alpha-fetoprotein (AFP) promotes resistance of hepatocellular carcinoma (HCC) cells to lenvatinib by regulating the activity of lactate dehydrogenase A (LDHA) and triggering the Warburg effect.
Weimei Xing, Fang Wang, Siren Feng, Xiaowei Li, Yuli Zhou, Huayi Wu, Bo Lin, Xu Dong, Mengsen Li, Mingyue Zhu   +9 more
doaj   +1 more source

The role and mechanism of CHST6-mediated lactation modification in lenvatinib resistance in hepatocellular carcinoma cells. [PDF]

Am J Transl Res
Wang D, Gao H, Li L.
europepmc   +1 more source

USP10 confers lenvatinib resistance in hepatocellular carcinoma by deubiquitinating the GPX2. [PDF]

Cell Oncol (Dordr)
Zhong CR, Qiu Z, Tang YJ, Lin Z, Tang D, Wan YL, Li GL.   +6 more
europepmc   +1 more source